Precision medicine in chronic obstructive pulmonary disease

Abstract Over the last 20 years, it has become possible to use a precision medicine approach to the management of chronic obstructive pulmonary disease (COPD). Clinical and physiological features as well as a blood biomarker can be used to target treatments to patients most likely to benefit and avoid treatment in patients less likely to benefit. Future advances in a precision medicine approach to COPD will depend on more precise characterization of individual patients, possibly using quantitative imaging, new physiological techniques, novel biomarkers and genetic profiling. Precision medicine has led to significant improvements in the management of COPD and clinicians should use all available information to optimize the treatment of individual patients.

[1]  Meilan K. Han,et al.  InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations , 2021, Respiratory Research.

[2]  J. de Vos,et al.  Targeted therapy in eosinophilic chronic obstructive pulmonary disease , 2021, ERJ Open Research.

[3]  S. Zhai,et al.  Procalcitonin for Antibiotic Prescription in Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective , 2020, Pulmonary Therapy.

[4]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[5]  Dave Singh,et al.  Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease , 2020, Allergy.

[6]  D. Lomas,et al.  Alpha1-Antitrypsin Deficiency. , 2020, The New England journal of medicine.

[7]  C. Brightling,et al.  Sputum microbiome profiling in COPD: beyond singular pathogen detection , 2020, Thorax.

[8]  M. Tobin,et al.  Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma , 2019, Allergy.

[9]  Meilan K. Han,et al.  Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.

[10]  K. Hood,et al.  C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. , 2019, The New England journal of medicine.

[11]  P. Frith,et al.  It is time for the world to take COPD seriously: a statement from the GOLD board of directors , 2019, European Respiratory Journal.

[12]  V. Backer,et al.  Benralizumab for the Prevention of COPD Exacerbations. , 2019, The New England journal of medicine.

[13]  B. Celli,et al.  Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. , 2019, American journal of respiratory and critical care medicine.

[14]  W. Boersma,et al.  CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions , 2019, European Respiratory Journal.

[15]  G. Criner,et al.  Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – Update 2019 , 2019, Respiration.

[16]  D. Halpin.  Palliative Care for Chronic Obstructive Pulmonary Disease. Signs of Progress, but Still a Long Way to Go. , 2018, American journal of respiratory and critical care medicine.

[17]  C. Farah,et al.  Bronchodilator Responses in Respiratory Impedance, Hyperinflation and Gas Trapping in COPD , 2018, COPD.

[18]  Yongjian Xu,et al.  Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study , 2018, The Lancet.

[19]  N. Roche,et al.  Defining the “Frequent Exacerbator” Phenotype in COPD: A Hypothesis‐Free Approach , 2017, Chest.

[20]  A. Dirksen,et al.  European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency , 2017, European Respiratory Journal.

[21]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[22]  T. H. Nguyen,et al.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.

[23]  O. Franco,et al.  Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease , 2017, European Respiratory Journal.

[24]  Meilan K. Han,et al.  Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort , 2017, The Lancet. Respiratory medicine.

[25]  J. Wedzicha,et al.  Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial , 2017, JAMA.

[26]  A. Pottegård,et al.  Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study , 2017, npj Primary Care Respiratory Medicine.

[27]  Meilan K. Han,et al.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts , 2017, American journal of respiratory and critical care medicine.

[28]  B. McManus,et al.  Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care , 2017, Chest.

[29]  M. Sanak,et al.  Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). , 2017, The Lancet. Respiratory medicine.

[30]  David M. Shade,et al.  A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. , 2016, The New England journal of medicine.

[31]  W. R. Wikoff,et al.  Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung , 2016, Thorax.

[32]  C. Harris,et al.  Biomarker development in the precision medicine era: lung cancer as a case study , 2016, Nature Reviews Cancer.

[33]  J. Parkhill,et al.  Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers , 2016, Thorax.

[34]  A. Sichelstiel,et al.  Microbiota Promotes Chronic Pulmonary Inflammation by Enhancing IL-17A and Autoantibodies. , 2016, American journal of respiratory and critical care medicine.

[35]  I. Pavord,et al.  Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.

[36]  Alan D. Lopez,et al.  Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013 , 2016, The Lancet.

[37]  Aziz Sheikh,et al.  Global and regional estimates of COPD prevalence: Systematic review and meta–analysis , 2015, Journal of global health.

[38]  M. Hyland,et al.  Understanding fear and anxiety in patients at the time of an exacerbation of chronic obstructive pulmonary disease: a qualitative study , 2015, JRSM open.

[39]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[40]  D. Longo,et al.  Precision medicine--personalized, problematic, and promising. , 2015, The New England journal of medicine.

[41]  Edwin K Silverman,et al.  CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. , 2015, Radiology.

[42]  D. Postma,et al.  Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.

[43]  I. Pavord,et al.  Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations , 2014, Chest.

[44]  D. Mannino,et al.  Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. , 2015, Chronic obstructive pulmonary diseases.

[45]  V. Pérez-Brocal,et al.  Severity-Related Changes of Bronchial Microbiome in Chronic Obstructive Pulmonary Disease , 2014, Journal of Clinical Microbiology.

[46]  F. Martinez,et al.  The role of the microbiome in exacerbations of chronic lung diseases , 2014, The Lancet.

[47]  A. Mira,et al.  Sputum microbiota in moderate versus severe patients with COPD , 2013, European Respiratory Journal.

[48]  V. Kim,et al.  Chronic bronchitis and chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[49]  D. Mannino,et al.  Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease , 2012, Thorax.

[50]  M. Mantero,et al.  Antibiotics as immunomodulant agents in COPD. , 2012, Current opinion in pharmacology.

[51]  L. Edwards,et al.  COPD association and repeatability of blood biomarkers in the ECLIPSE cohort , 2011, Respiratory research.

[52]  D. Mannino,et al.  Lung function impairment, COPD hospitalisations and subsequent mortality , 2011, Thorax.

[53]  J. Curtis,et al.  Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD , 2011, PloS one.

[54]  A. Yohannes,et al.  Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles , 2010, International journal of geriatric psychiatry.

[55]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[56]  R. Rodríguez-Roisín,et al.  Frequent Chronic Obstructive Pulmonary Disease Exacerbators: How Much Real, How Much Fictitious? , 2010, COPD.

[57]  T. Omachi,et al.  Influence of anxiety on health outcomes in COPD , 2010, Thorax.

[58]  D. Halpin,et al.  Palliative and end-of-life care for patients with respiratory disease , 2009 .

[59]  J. Coyne,et al.  Depressive symptoms as predictors of mortality in patients with COPD. , 2009, Chest.

[60]  J. Bourbeau,et al.  Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. , 2008, American journal of respiratory and critical care medicine.

[61]  G. Donaldson,et al.  Relationship between depression and exacerbations in COPD , 2008, European Respiratory Journal.

[62]  D. Postma,et al.  Increased systemic inflammation is a risk factor for COPD exacerbations. , 2008, Chest.

[63]  T. Ng,et al.  Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.

[64]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[65]  D. Halpin.  A further step in the process of developing better service and standards of care for patients with COPD , 2004 .

[66]  Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. , 2004, Thorax.

[67]  H. Danahay,et al.  IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[68]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[69]  B. Celli,et al.  Cough and phlegm are important predictors of health status in smokers without COPD. , 2002, Chest.

[70]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[71]  A. Crockett,et al.  Domiciliary oxygen for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[72]  F. Harrell,et al.  Dying with Lung Cancer or Chronic Obstructive Pulmonary Disease: Insights from SUPPORT , 2000, Journal of the American Geriatrics Society.

[73]  Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. , 1997, Bulletin of the World Health Organization.

[74]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.